News

The first participants were enrolled into a Phase 1 clinical trial of the University of Queensland’s (UQ) COVID-19 vaccine candidate on July 13.

A new study in the Biophysical Journal outlines the work of scientists who have created a series of compounds that could serve as an alternative synthetic energy source for myosin.

A compound commonly found in pickled capers has been shown to activate proteins required for normal human brain and heart activity, and may even lead to future therapies for the treatment of epilepsy and abnormal heart rhythms.

A cost-benefit analysis study has determined that esketamine, a nasal spray used to treat severe depression, is currently too expensive for widespread use.

Researchers show that giving the antimalarial drug hydroxychloroquine to pregnant women who previously had a child affected by congenital heart block reduced the likelihood that the condition recurred in a subsequent pregnancy by 50%.

Scientist have show that an already approved drug from cancer treatment could help against adenovirus infection by strengthening the body's viral defenses.

Critically ill COVID-19 patients who received a single dose of intravenous tocilizumab were 45% less likely to die overall, and more likely to be out of the hospital or off a ventilator one month after treatment, compared with those who didn't receive the drug, according to new research conducted by University of Michigan scientists.

Biologists and bioengineers at EPFL have designed a new method for growing simplified human mini-livers. Their process is a potentially important breakthrough in the quest for transplantable lab-grown tissues.

In a new study, scientists make some interesting discoveries surrounding a little-studied liver protein. Their findings suggest that it might be responsible for the neurological benefits associated with exercise in the aging brain.

A recent preprint study indicates that there is a rapid decline in the levels of SARS-CoV-2 neutralizing antibodies during the weeks following initial infection. This raises questions over the potential for re-infection, the effectiveness that may be expected from vaccination and the viable window for antibody testing in disease surveillance.